Microcap Ledger

Tickers · $VVOS

Vivos Therapeutics, Inc. $VVOS

By Microcap Ledger desk · CIK 0001716166

Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange
Nasdaq Capital Market
Sector
Surgical & Medical Instruments & Apparatus
Headquarters
Littleton, CO
Fiscal year end
December 31
Shares outstanding
20,118,023 [10-Q 2026-08-14]
as of 2026-08-13

Sources: [10-K 2026-04-15]

What the company doesAI summary of filing

Vivos Therapeutics is a revenue-stage medical technology and healthcare services company that develops and sells oral appliances and related therapeutic treatments for obstructive sleep apnea and related breathing disorders. The company's primary products are proprietary C.A.R.E. oral appliances (DNA, mRNA, and mmRNA devices) that are FDA-cleared for treating mild to severe OSA in adults and children, along with adjunctive therapies and diagnostic tools. The company generates revenue through appliance sales to trained dentists, diagnostic and treatment services from acquired or managed sleep centers, and ancillary services including home sleep testing, billing services, and myofunctional therapy. Since 2024, Vivos has pivoted toward a medical-provider focused model emphasizing direct acquisition and management of sleep medical practices and dental and medical service organizations, exemplified by its 2025 acquisition of The Sleep Center of Nevada, which generated approximately $6.8 million in revenue in 2025. [10-K 2026-04-15]

Segments: C.A.R.E. oral appliances (DNA, mRNA, mmRNA), Sleep Center and MSO/DSO operations, VivoScore home sleep testing, Treatment Navigator and billing services

Financial health

From XBRL company facts (USD)
PeriodRevenueNet incomeOperating cash flowCashFiling
6 months to Jun 2026$10.29M−$13.16M −$9.16M$1.77M[10-Q 2026-08-14]
FY ended Dec 2025$17.44M−$21.17M −$15.26M$2.03M[10-K 2026-04-15]
FY ended Dec 2024$15.03M−$11.14M −$12.69M$6.26M[10-K 2026-04-15]
Quarterly cash burn
−$4.58M
Cash runway Estimate
~1.2 months

Estimate: cash at the end of the period (6 months to Jun 2026) divided by the average monthly operating cash outflow over that period. Ignores any cash raised or spent since, and any financing.

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
DateShares outstandingFiling
2024-11-144,835,300[10-Q 2024-11-14]
2025-03-315,889,520[10-K 2025-03-31]
2025-05-155,889,520[10-Q 2025-05-15]
2025-08-187,504,807[10-Q 2025-08-19]
2025-11-148,988,106[10-Q 2025-11-19]
2026-04-1513,486,006[10-K 2026-04-15]
2026-05-2013,894,600[10-Q 2026-05-20]
2026-08-1320,118,023[10-Q 2026-08-14]
Shelf registration
S-3 filed 2026-02-17; declared effective 2026-05-08 [S-3 2026-02-17]

Listing status

Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-06-08. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.

DateEventDetailsDeadlineFiling
2026-06-088-K Item 3.01Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing—[8-K 2026-06-08]
2026-04-228-K Item 3.01Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing—[8-K 2026-04-22]

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
DateInsiderTypeSharesPriceFiling
2026-07-31Amman Bradford K.grant250,000$0.41[4 2026-08-26]
2026-06-30Huntsman Ronald Kirkother85,910$0.58[4 2026-09-18]
2026-03-31Skaff Michael Cbuy1,044,777$1.34[4 2026-04-02]
2026-03-31Skaff Michael Cbuy308,848$1.34[4 2026-04-02]

Catalysts and calendar

Facts as of . Small caps move fast; check the latest filings.